Pacira BioSciences, Inc.

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
26.33 ^USD	+3.25%		+0.88%	-21.96%

Mar. 13	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Mar. 13	Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	MT

Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021

February 24, 2022 at 08:02 am EST

Pacira BioSciences, Inc. reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported revenue was USD 159.19 million compared to USD 130.97 million a year ago. Net loss was USD 5.13 million compared to net income of USD 14.51 million a year ago.

Basic loss per share from continuing operations was USD 0.12 compared to basic earnings per share from continuing operations of USD 0.33 a year ago. Diluted loss per share from continuing operations was USD 0.12 compared to diluted earnings per share from continuing operations of USD 0.32 a year ago.

Latest news about Pacira BioSciences, Inc.

Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM	Mar. 13
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	Mar. 13	MT
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis	Mar. 13	DJ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	Mar. 13	CI
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing	Mar. 08	MT
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating	Mar. 01	MT
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	Feb. 29	MT
Transcript : Pacira BioSciences, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024	Feb. 29	CI
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M	Feb. 29	MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85	Feb. 29	MT
North American Morning Briefing : Fed's Preferred -2-	Feb. 29	DJ
Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy	Feb. 15	CI
Pacira BioSciences Awarded Group Purchasing Agreement with Premier	Feb. 07	MT
Pacira BioSciences Receives Brand Pharmaceuticals Agreement With Premier, Inc	Feb. 07	CI
Transcript : Pacira BioSciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM	Jan. 10
Pacira BioSciences Says Preliminary Data Show 2023 Sales Rose 1.2% From Year Earlier, Topping Consensus	Jan. 04	MT
Pacira Reports Unaudited Preliminary Sales Results for the Fourth Quarter and Full-Year Ended December 31, 2023	Jan. 04	CI
RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating	Jan. 03	MT
Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024	Dec. 21	CI
Pacira Biosciences, Inc. Appoints Frank D. Lee as Member of the Board, Effective January 2, 2024	Dec. 21	CI
Pacira BioSciences Names Frank D. Lee CEO, Board Member	Dec. 21	MT
Raymond James Initiates Pacira BioSciences With Outperform Rating, Price Target is $42	Dec. 20	MT

Chart Pacira BioSciences, Inc.

Duration

Period

More charts

Company Profile

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Pacira BioSciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.5 USD

Average target price

45.73 USD

Spread / Average Target

+79.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PACIRA BIOSCIENCES, INC.	-21.96%	1.19B
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B

Other Pharmaceuticals